In our most recent report on Merge Healthcare (MRGE), we upgraded the stock to a HOLD based upon the improved outlook for medical information technology and recent business developments within the company.

MRGE’s Q109 results showed modest improvements in both its top and bottom lines, reporting its third consecutive quarter of net income. This is less than a year after the company received a much needed cash infusion ($20 million), turned over its management team, and instituted a severe restructuring program. The results have begun paying dividends with an increase in margins and positive cash from operations.

More importantly, the company tapped the Chinese healthcare market by forming an alliance with the leading healthcare IT provider there. We think that this will change the face of MRGE. Combined with recently announced stimulus spending in both the U.S. and China, the alliance is likely to yield dramatic improvements in its top line.

MRGE is presently trading at a P/S multiple of approximately 2.9x for 2009, close to both the industry mean and the comparables’ mean P/S multiple of 3.0x. We think that the stock should trade at 5% premium to its comparables’ mean P/S multiple. This drives to a target P/S multiple of 3.15x and a target price of approximately $3.45. We upgrade this stock to a Hold.

Read the full analyst report on “MRGE”
Zacks Investment Research

Last 5 posts by Zacks Market Commentaries

• 3 Turkeys to Short Right Now - Investment Ideas - November 26th, 2009
• VIP Falls Behind Expectations - Analyst Blog - November 25th, 2009
• J. Crew Beats Zacks Estimates - Analyst Blog - November 25th, 2009
• No Change in Deere's Outlook - Analyst Blog - November 25th, 2009
• Sprint Acquires Virgin Mobile USA - Analyst Blog - November 25th, 2009